Minerva Neuroscie (NERV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 26,629 | 30,981 | 34,918 | 41,013 | 47,004 |
| TOTAL | $27,936 | $31,409 | $35,621 | $42,002 | $48,225 |
| Non-Current Assets | |||||
| PPE Net | 7 | 8 | 10 | 11 | 12 |
| Intangibles | 14,869 | 14,869 | 14,869 | 14,869 | 14,869 |
| Other Non-Current Assets | 0 | 4 | 11 | 17 | 24 |
| TOTAL | $14,876 | $14,882 | $14,890 | $14,897 | $14,905 |
| Total Assets | $42,812 | $46,291 | $50,510 | $56,900 | $63,130 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 553 | 828 | 1,436 | 1,805 | 1,395 |
| Accrued Expenses | 3,930 | 3,375 | 1,395 | 1,535 | 1,955 |
| TOTAL | $4,483 | $4,203 | $2,831 | $3,340 | $3,350 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 60,000 | 86,579 | 84,267 | 82,017 | 79,827 |
| TOTAL | $60,000 | $86,579 | $84,267 | $82,017 | $79,827 |
| Total Liabilities | $64,483 | $90,783 | $87,098 | $85,357 | $83,176 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 6,993 | 6,993 | 6,993 | 6,993 | 6,993 |
| Common Shares | 1 | 1 | 1 | 1 | 1 |
| Retained earnings | -391,105 | -413,618 | -405,384 | -396,815 | -387,793 |
| TOTAL | $-21,671 | $-44,492 | $-36,587 | $-28,458 | $-20,046 |
| Total Liabilities And Equity | $42,812 | $46,291 | $50,511 | $56,900 | $63,130 |